therapeutic action: fungicidal activity

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health problem, particularly for people with weakened immune systems, causing millions of deaths annually. Current antifungal medications are limited and increasingly ineffective due to drug-resistant fungi. This special issue explores new treatment strategies including novel drugs, combination therapies, and innovative approaches like nanoparticles and antimicrobial peptides to combat these serious infections.

Read More »

Staurosporine as an Antifungal Agent

mycolabadmin

Staurosporine is a natural compound produced by soil bacteria that can kill fungi. Scientists originally discovered it in 1977 and found it works by blocking proteins called kinases that fungi need to survive. Recent research shows it could be useful against drug-resistant fungal infections, especially when combined with other antifungal medicines. However, it needs to be modified to make it safer for human use.

Read More »

Invasive Saprochaete capitata Infection in an Immunocompromised Patient With Acute Myeloid Leukemia: A Case Report

mycolabadmin

A 46-year-old man with blood cancer developed a serious fungal infection caused by Saprochaete capitata during chemotherapy. This rare but dangerous fungus was found in his blood and lungs, causing fever and breathing problems. The patient was successfully treated with a combination of two antifungal medications and fully recovered, though this infection typically has a high death rate.

Read More »

Polyherbal nanoformulation: a potent antifungal agent on fungal pathogens of Coffea arabica

mycolabadmin

Researchers developed an eco-friendly nano-formulation from Triphala to fight fungal diseases that harm coffee plants. The treatment effectively stopped the growth of five different harmful fungi that infect coffee leaves. This green nanotechnology approach offers farmers a safer, environmentally friendly alternative to chemical fungicides that can pollute the environment and harm human health.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Read More »

In vitro activity of SF001: a next-generation polyene versus amphotericin B

mycolabadmin

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Read More »
Scroll to Top